文献速递骨质疏松与代谢性骨病

药理浓度褪黑素通过减弱细胞内活性氧抑制破骨细胞生成

Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.
PubMed 文献 · Osteoporos Int · 2017-09-27

本研究从C57BL/6小鼠股骨和胫骨分离原代骨髓单核细胞(BMMs),在生理浓度(0.01–10 nM)或药理浓度(1–100 μM)褪黑素存在下诱导破骨细胞分化。结果显示仅药理浓度褪黑素以剂量依赖方式显著抑制破骨细胞形成,该作用涉及抑制NF-κB信号通路,由活性氧(ROS)介导而非SIRT1非依赖途径。

要点

  • 药理浓度(1–100 μM)而非生理浓度(0.01–10 nM)褪黑素显著抑制破骨细胞生成。
  • 褪黑素下调TRAP阳性细胞数及破骨细胞特异性标志物基因表达。
  • 褪黑素抑制破骨分化涉及NF-κB信号通路抑制,由ROS介导而非SIRT1非依赖途径。

核心结论

  • 药理剂量褪黑素通过ROS介导而非SIRT1非依赖途径直接抑制BMMs的破骨细胞生成。

研究设计与样本

  • 从C57BL/6小鼠股骨和胫骨分离原代BMMs,在生理浓度(0.01–10 nM)或药理浓度(1–100 μM)褪黑素存在下诱导多核破骨细胞。

主要发现

  • 药理浓度而非生理浓度褪黑素以剂量依赖方式显著抑制破骨细胞形成。
  • 褪黑素处理BMMs中TRAP阳性细胞数及破骨细胞特异性标志物基因表达显著下调。
  • 褪黑素介导的破骨分化抑制涉及NF-κB信号通路抑制。
  • SIRT1抑制剂处理不影响破骨细胞分化,但补充外源性过氧化氢后观察到褪黑素抑制的破骨细胞生成部分恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis is linked to age-related decline of melatonin production; however, the direct effects of melatonin on osteoclastogenesis remain unknown. Our study demonstrates that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibits osteoclastogenesis. Melatonin-mediated anti-osteoclastogenesis involves a reactive oxygen species (ROS)-mediated but not a silent information regulator type 1 (SIRT1)-independent pathway. INTRODUCTION: Osteoporosis is a bone disorder linked to impaired bone formation and excessive bone resorption. Melatonin has been suggested to treat osteoporosis due to its beneficial actions on osteoblast differentiation. However, the direct effects of melatonin on osteoclastogenesis in bone marrow monocytes (BMMs) remain unknown. This study was to investigate whether melatonin at either physiological or pharmacological concentrations could affect osteoclast differentiation. METHODS: Primary BMMs were isolated from the femurs and tibias of C57BL/6 mice and were induced toward multinucleated osteoclasts, in the presence of melatonin at either physiological (0.01 to 10 nM) or pharmacological (1 to 100 μM) concentrations. Tartrate-resistant acid phosphatase (TRAP) staining was used to label multinucleated osteoclasts and the levels of osteoclast-specific genes were evaluated. To further explore the underlying mechanisms, the roles of silent information regulator type 1 (SIRT1) and reactive oxygen species (ROS) were evaluated. RESULTS: We found that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibited osteoclast formation in a dose-dependent manner. The number of TRAP-positive cells and the gene expression of osteoclast-specific markers were significantly downregulated in melatonin-treated BMMs. The melatonin-mediated repression of osteoclast differentiation involved the inhibition of the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. The treatment with SIRT1 inhibitors did not affect osteoclast differentiation but, when supplemented with exogenous hydrogen peroxide, a partial rescue of melatonin-suppressed osteoclastogenesis was observed. CONCLUSION: Melatonin at pharmacological doses directly inhibited osteoclastogenesis of BMMs by a ROS-mediated but not a SIRT1-independent pathway.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Zhou L, Chen X, Yan J, et al. Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS. Osteoporos Int. 2017. PMID: 28956094. doi:10.1007/s00198-017-4127-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。